title: [Prolonged partial remission of a hepatocellular carcinoma treated with adriamycin and recombinant human alpha-2 interferon].
abstract: Adriamycin is one of the chemotherapeutic agent often administered in the treatment of unresectable hepatocellular carcinoma. On monotherapy, the reported rate response is between 0 to 15 p. cent, without improvement on survival. Its combination with other cytotoxic molecules, such as interferon, has been suggested to improve the percentage of response rates. We present the case of a 73 years old man, who underwent a prolonged partial response of a hepatocellular carcinoma with adriamycin and recombinant human interferon alpha-2.
authors.affiliation: Service d'Hépatogastroentérologie, Hôpital Tenon, Paris.
authors.forename: X
authors.initials: X
authors.lastname: Amiot
authors.forename: J D
authors.initials: JD
authors.lastname: Grangé
authors.forename: F
authors.initials: F
authors.lastname: Boudghene
authors.forename: D
authors.initials: D
authors.lastname: Lamarque
authors.forename: J P
authors.initials: JP
authors.lastname: Lotz
authors.forename: V
authors.initials: V
authors.lastname: Izrael
authors.forename: F
authors.initials: F
authors.lastname: Bodin
mesh_terms: D000368:Aged; D000437:Alcoholism / Q000150:complications*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins; D012074:Remission Induction / Q000379:methods*; D014057:Tomography, X-Ray Computed
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; D004317:Doxorubicin
vernacular_title: Rémission partielle prolongée d'un carcinome hépatocellulaire traité par adriamycine et interféron alpha-2 human recombinant.